MDS: Refining existing therapy through improved biologic insights

Blood Reviews

Volumn 26, Issue 2, 2012, Pages 73-80

  Schecter, Jordan ^a   Galili, Naomi ^a   Raza, Azra ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Hypomethylating agents; Lenalidomide; Myelodysplastic syndromes; Refining therapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; DNA; DNA METHYLTRANSFERASE 3A; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; LENALIDOMIDE; PLACEBO; THALIDOMIDE; TUMOR NECROSIS FACTOR; VASCULOTROPIN;

ANEMIA; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD TRANSFUSION; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME 5Q; CHROMOSOME DELETION 5; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTINUOUS INFUSION; CYTOKINE PRODUCTION; DNA METHYLATION; DNA SYNTHESIS; DNMT3A GENE; DRUG APPROVAL; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; ERYTHEMA NODOSUM LEPROSUM; FOOD AND DRUG ADMINISTRATION; GENE; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; INHIBITION KINETICS; LEPROSY; MORNING SICKNESS; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SYNTHESIS INHIBITION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH EXCESS BLASTS IN TRANSFORMATION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REMISSION; SURVIVAL RATE; TERATOGENICITY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; HUMANS; MYELODYSPLASTIC SYNDROMES; QUALITY OF LIFE; SURVIVAL RATE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84856533651     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2011.11.001     Document Type: Article

References (47)

1. Bianco P. Bone and the hematopoietic niche: a tale of two stem cells. Blood 2011, 117(20):5281-5288. [Epub 2011 Mar 15].
2. Raaijmakers M.H., Mukherjee S., Guo S., Zhang S., Kobayashi T., Schoonmaker J.A., et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature 2010, 464(7290):852-857. [Epub 2010 Mar 21].
3. Raza A., Gezer S., Mundle S., Gao X.Z., Alvi S., Borok R., et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995, 86(1):268-276.
4. Shetty V., Mundle S., Alvi S., Showel M., Broady-Robinson L., Dar S., et al. Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res 1996, 20(11-12):891-900.
5. Raza A., Meyer P., Dutt D., Zorat F., Lisak L., Nascimben F., et al. Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001, 98(4):958-965.
6. List A., Kurtin S., Roe D.J., Buresh A., Mahadevan D., Fuchs D., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352(6):549-557.
7. Raza A., Reeves J.A., Feldman E.J., Dewald G.W., Bennett J.M., Deeg H.J., et al. List AF.Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008, 111(1):86-93. [Epub 2007 Sep 24].
8. List A., Dewald G., Bennett J., Giagounidis A., Raza A., Feldman E., et al. Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355(14):1456-1465.
9. Fenaux P., Giagounidis A., Selleslag D., Beyne-Rauzy O., Mufti G., Mittelman M., et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood 2011, 118(14):3765-3776.
10. Ebert B.L., Galili N., Tamayo P., Bosco J., Mak R., Pretz J., et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008, 5(2):e35.
11. Pellagatti A., Jädersten M., Forsblom A.M., Cattan H., Christensson B., Emanuelsson E.K., et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients. Proc Natl Acad Sci U S A 2007, 104(27):11406-11411.
12. Gandhi A.K., Kang J., Verhelle D., Stirling D.I., Schafer P.H. Inhibition of cell proliferation by lenalidomide is associated with stimulation of Egr1 transcriptional activity in a chromosome 5 deleted Burkitt's lymphoma and multiple myeloma cell line. J Clin Oncol Meet Abstr 2007, 25(18 suppl).
13. Wei S., Chen X., Rocha K., Epling-Burnette P.K., Djeu J.Y., Liu Q., et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A 2009, 106(31):12974-12979.
14. Hideshima Teru, Chauhan Dharminder, Shima Yoshihito, Raje Noopur, Davies Faith E., Tai Yu-Tzu, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2002, 96:2943-2950.
15. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Richardson P.G., Hideshima T., et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99(12):4525-4530.
16. Allampallam K., Shetty V., Mundle S., Dutt D., Kravitz H., Reddy P.L., et al. Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol 2002, 75(3):289-297.
17. Marriott J.B., Clarke I.A., Dredge K., Muller G., Stirling D., Dalgleish A.G. Thalidomide and its analogues have distinct and opposing effects on TNF-alpha and TNFR2 during co-stimulation of both CD4(+) and CD8(+) T cells. Clin Exp Immunol 2002, 130(1):75-84.
18. Davies F.E., Raje N., Hideshima T., Lentzsch S., Young G., Tai Y.T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98(1):210-216.
19. Dredge K., Marriott J.B., Todryk S.M., Muller G.W., Chen R., Stirling D.I., et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 2002, 168(10):4914-4919.
20. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994, 91(9):4082-4085.
21. Zorat F., Shetty V., Dutt D., Lisak L., Nascimben F., Allampallam K., et al. The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes. Br J Haematol 2001, 115(4):881-894.
22. Giagounidis A.A., Germing U., Haase S., Hildebrandt B., Schlegelberger B., Schoch C., et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 2004, 18(1):113-119.
23. Gupta D., Treon S.P., Shima Y., Hideshima T., Podar K., Tai Y.T., et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001, 15(12):1950-1961.
24. Mitsiades C.S., Mitsiades N.S., Richardson P.G., Munshi N.C., Anderson K.C. Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem 2007, 101(4):950-968.
25. Breitkreutz I., Raab M.S., Vallet S., Hideshima T., Raje N., Mitsiades C., et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008, 22(10):1925-1932. [Epub 2008 Jul 3].
26. Jakubikova J., Adamia S., Kost-Alimova M., Klippel S., Cervi D., Daley J.F., et al. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood 2011, 117(17):4409-4419. [Epub 2011 Feb 14].
27. Silverman L.R., McKenzie D.R., Peterson B.L., Holland J.F., Backstrom J.T., Beach C.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006, 24(24):3895-3903. Cancer and Leukemia Group B.
28. Kim D.Y., Lee J.H., Lee J.H., Lee K.H., Kim Y.K., Ahn J.S., et al. Korean Society of Hematology AML/MDS Working Party. Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine. Ann Hematol 2009, 89(1):15-23.
29. Itzykson R., Thépot S., Quesnel B., Dreyfus F., Beyne-Rauzy O., Turlure P., et al. Groupe Francophone des Myelodysplasies (GFM). Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 2011, 117(2):403-411.
30. Moon J.H., Kim S.N., Kang B.W., Chae Y.S., Kim J.G., Baek J.H., et al. Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment. Ann Hematol 2010, 89(7):681-689.
31. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006, 106(8):1794-1803.
32. Wijermans P.W., Lübbert M., Verhoef G., Klimek V., Bosly A. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients. Ann Hematol 2005, 84(Suppl 1):9-17.
33. Kantarjian H.M., O'Brien S., Shan J., Aribi A., Garcia-Manero G., Jabbour E., et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer 2007, 109(2):265-273.
34. Taylor S.M., Jones P.A. Multiple new phenotypes induced in 10T1/2 and 3T3 cells treated with 5-azacytidine. Cell 1979, 17(4):771-779.
35. Ghoshal K., Datta J., Majumder S., Bai S., Kutay H., Motiwala T., et al. Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol 2005, 25(11):4727-4741.
36. Yang X., Lay F., Han H., Jones P.A. Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci 2010, 31(11):536-546. [Epub 2010 Sep 16].
37. Israili Z.H., Vogler W.R., Mingioli E.S., Pirkle J.L., Smithwick R.W., Goldstein J.H. The disposition and pharmacokinetics in humans of 5-azacytidine administered intravenously as a bolus or by continuous infusion. Cancer Res 1976, 36(4):1453-1461.
38. Eden A., Gaudet F., Waghmare A., Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003, 300(5618):455.
39. Figueroa M.E., Skrabanek L., Li Y., Jiemjit A., Fandy T.E., Paietta E., et al. MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 2009, 114(16):3448-3458. [Epub 2009 Aug 3].
40. Tien H.F., Tang J.H., Tsay W., Liu M.C., Lee F.Y., Wang C.H., et al. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol 2001, 112(1):148-154.
41. Kantarjian H.M., O'Brien S., Cortes J., Giles F.J., Faderl S., Issa J.P., et al. Results of decitabine (5-aza-2?-deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 2003, 98:522-528.
42. Borthakur G., Ahdab S.E., Ravandi F., Faderl S., Ferrajoli A., Newman B., et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma 2008, 49(4):690-695.
43. Shen L., Kantarjian H., Guo Y., Lin E., Shan J., Huang X., et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010, 28(4):605-613. [Epub 2009 Dec 28. Erratum in: J Clin Oncol. 2010 Jun 20;28(18):3098].
44. Yamashita Y., Yuan J., Suetake I., Suzuki H., Ishikawa Y., Choi Y.L., et al. Array-based genomic resequencing of human leukemia. Oncogene 2010, 29(25):3723-3731. [Epub 2010 Apr 19].
45. Ley T.J., Ding L., Walter M.J., McLellan M.D., Lamprecht T., Larson D.E., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010, 363(25):2424-2433. [Epub 2010 Nov 10].
46. Ewalt M., Galili N., Mumtaz M., Churchill M., Rivera S., Borot F., et al. DNMT3a mutations in high-risk myelodysplastic syndrome parallel those found in acute myeloid leukemia. Blood Cancer J 2011, 1:e9. 10.1038/bcj.2011.7.
47. Walter M.J., Ding L., Shen D., Shao J., Grillot M., McLellan M., et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011, 25(7):1153-1158. 10.1038/leu.2011.44. Epub 2011 Mar 18.